Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc.    MRK

MERCK & CO., INC.

(MRK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

MERCK & CO INC : Goldman Sachs remains Neutral

10/29/2019 | 07:42am EST

Goldman Sachs's research confirms his advice and maintains his neutral opinion on the stock.. The target price remains unchanged at USD 89.


© MarketScreener with dpa-AFX Analyser 2019
Stocks mentioned in the article
ChangeLast1st jan.
MERCK & CO., INC. 0.34% 81.83 Delayed Quote.-10.34%
THE GOLDMAN SACHS GROUP, INC. 2.40% 237.65 Delayed Quote.0.28%
All news about MERCK & CO., INC.
07:13aMERCK : Announces Sale of its Direct Equity Investment in Moderna
PU
11/30MERCK : to Present at the 2020 Evercore ISI 3rd Annual HealthCONx Virtual Confer..
BU
11/27OF MOLECULES & MEDICINE : Dr Maurice Hilleman ("The Father Of Modern Vaccines")
AQ
11/24MERCK : Submits Applications for Licensure of V114, the Company's Investigationa..
AQ
11/24CORCEPT THERAPEUTICS INCORPORATED : Appoints Gillian M. Cannon, PhD, to Board of..
AQ
11/24MERCK : to Acquire OncoImmune
AQ
11/23GLOBAL MARKETS LIVE: Boeing’s 737 Max to resume flights in Europe, Merck’s la..
11/23MERCK : Correction to Merck to Buy OncoImmune Article
DJ
11/23Merck to Buy OncoImmune for $425 Million Amid Race for Covid-19 Treatments --..
DJ
11/23MERCK : Applies in U.S., Europe to License V114 Pneumococcal Conjugate Vaccine
DJ
More news
Financials (USD)
Sales 2020 48 179 M - -
Net income 2020 12 009 M - -
Net Debt 2020 14 601 M - -
P/E ratio 2020 17,3x
Yield 2020 2,98%
Capitalization 206 B 206 B -
EV / Sales 2020 4,59x
EV / Sales 2021 4,23x
Nbr of Employees 71 000
Free-Float 70,7%
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | MarketScreener
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 22
Average target price 96,33 $
Last Close Price 81,55 $
Spread / Highest target 31,2%
Spread / Average Target 18,1%
Spread / Lowest Target 4,23%
EPS Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Sandy Tremps Vice President-R&D IT CIO
Thomas Henry Glocer Independent Director
Leslie A. Brun Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK & CO., INC.-10.34%206 324
JOHNSON & JOHNSON1.08%388 168
ROCHE HOLDING AG-4.59%284 650
PFIZER, INC.6.17%219 056
NOVARTIS AG-11.46%205 415
ABBVIE INC.17.51%183 680